Brazilian Journal of Pharmaceutical Sciences
Print version ISSN 1984-8250
BARBOSA, Maria Letícia de Castro et al. Therapeutic approaches for tumor necrosis factor inhibition. Braz. J. Pharm. Sci. [online]. 2011, vol.47, n.3, pp. 427-446. ISSN 1984-8250. http://dx.doi.org/10.1590/S1984-82502011000300002.
Tumor necrosis factor (TNF) consists of an inflammatory cytokine essential for homeostasis and organism defense. Despite its physiological relevance, both increased biosynthesis and release of TNF lead to the exacerbation of inflammatory and oxidative responses, which are related to the pathogenesis of a host of diseases of an inflammatory, autoimmune and/or infectious nature. In this context, effective therapeutic approaches for the modulation of TNF have been the focus of research efforts. Approximately one million individuals worldwide have been treated with biotechnological inhibitors of this cytokine, the so-called anti-TNF biopharmaceuticals. However, given the high risk of infection and the limitations related to cost and administration routes, new therapeutic approaches aimed at biological targets that directly or indirectly modulate the production and/or activation of TNF appear promising alternatives for the discovery of new anti-inflammatory and immunomodulatory orally active drugs and are therefore discussed in this paper.
Keywords : Tumor necrosis factor; TACE; p38 MAPK; NF-κB; cAMP; Phosphodiesterase; Adenosine receptor.